Drugs / NELIVAPTAN
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01606384 | Dec 2006 → Aug 2007 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00374166 | Aug 2006 → Feb 2008 | anxiety disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00361491 | Aug 2006 → Sep 2007 | depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00358631 | Jul 2006 → Dec 2007 | depressive disorder | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NELIVAPTAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL582857 ↗ |
| Known as | SR-149415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL582857 ↗ |
| Known as | SSR149415 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00374166 ↗ |
| Action | Inhibit | “The vasopressin V(1b) receptor antagonist SSR149415” PMID 23146246 ↗ Oct 20121“Vasopressin V1b receptor antagonist” CHEMBL582857 ↗ |
| Modality | Small molecule | “the first nonpeptide vasopressin V(1b) receptor antagonist, SSR149415” PMID 23146246 ↗ Oct 2012 |
| Target | AVPR1B | “Vasopressin V1b receptor antagonist” CHEMBL582857 ↗ |